Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism

Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes - ScienceDirect

PDF) Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases

Identification of the specific causes of polysorbate 20

Polysorbate, the Good, the Bad and the Ugly American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology

Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway. - Abstract - Europe PMC

Considerations for the Use of Polysorbates in Biopharmaceuticals

Micellar Morphology of Polysorbate 20 and 80 and Their Ester Fractions in Solution via Small-Angle Neutron Scattering - Journal of Pharmaceutical Sciences

US20210268073A1 - Methods of reducing polysorbate degradation in drug formulations - Google Patents

Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism